PwC's Next in Health

Join Glenn Hunzinger and Dan Farrell as they discuss why 2026 could mark a rebound year for health services dealmaking—driven by higher-quality assets, improving market conditions, and the growing role of technology and AI. They explore how investors are rethinking value creation ...  Show more

Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy. Discussion highlights: ...  Show more

What will healthcare look like a decade from now? Host Glenn Hunzinger is joined by Greg Rotz, Pharmaceutical and Life Sciences Advisory Leader and Thom Bales, Principal, Health Services Advisory Leader, as they dive into the future of health—one driven by smarter tech, empowered ...  Show more

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, sits down with Nichole Montgomery, Shannon O’Shea, and Phil Sclafani to unpack the sweeping implications of the newly signed One Big Beautiful Bill Act (OBBBA). With nearly a third of the bill dedicated to healthcare, th ...  Show more

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, connects with Nick Donkar, PwC’s U.S. Health Services Deals Leader, and Roel Van den Akker, PwC’s Pharma and Life Sciences Deals Leader, to discuss the 2025 midyear deals outlook across health services and pharma and lif ...  Show more